Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Prednisone × Thoracic × Clear all

Phase

Phase 2 4 Phase 1 3 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7 Other hematologic neoplasm 6 Genitourinary 5 Plasma cell 3 Dermatologic 2 Thoracic 1

Conditions

Pneumonia 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1

Interventions

Cisplatin 14 Pemetrexed 12 Carboplatin 12 Erlotinib Hydrochloride 9 icotinib 8 Propofol 6 Gefitinib 6 Docetaxel 6 endostar protein 5 Endostatins 5 anlotinib 4 Saline Solution 4 tislelizumab 3 pembrolizumab 3 durvalumab 3 Zoledronic Acid 3 Vinorelbine 3 Sevoflurane 3 Radiotherapy 3 Paclitaxel 3 Nivolumab 3 Gemcitabine 3 Afatinib 3 Acetaminophen 3 trilaciclib 2 pegfilgrastim 2 osimertinib 2 lorlatinib 2 atezolizumab 2 Surgical Procedures, Operative 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04036721 2023-02-23

PROS-CONS

National Institute for Tuberculosis and Lung Diseases, Poland

Phase 4 Suspended

Lung Neoplasms, Pneumonia, Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡